Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) announced its quarterly earnings results on Tuesday. Here are the key takeaways from Palvella Therapeutics’ conference call:Get Palvella Therapeutics alerts:QTORIN rapamycin’s NDA remains on track for completion in the second half of 2026, with potential FDA approval in the first half of 2027. Palvella Therapeutics has a 12 month low of $36.93 and a 12 month high of $161.38. Mariner LLC bought a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at about $1,299,000. Read MoreReceive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.